Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds.

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second ...

Regeneron remains a 'Strong Buy' amid investor concerns and strong drug performances. Read here for more financial analysis ...

The US FDA has expanded the approval of Regeneron Pharmaceuticals' fully human monoclonal antibody, Evkeeza (evinacumab-dgnb) ...

Regeneron Pharmaceuticals expects to record an acquired in-process research-and-development charge of approximately $83 million in the third quarter.

Compared to the aggregate P/E ratio of the 31.18 in the Biotechnology industry, Regeneron Pharmaceuticals Inc. has a lower ...

As academic researchers experience a worsening funding crunch and pharma companies are increasingly hungry for large, ...

In late September 2025, Regeneron Pharmaceuticals announced expanded US FDA approval of Evkeeza for very young children with ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder affecting soft tissue significantly reduced abnormal bone formation, meeting the main goal of a ...

Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...